Private Equity Looking for Interns - Gilde Healthcare

Private Equity Looking for Interns

2. August 2017

Gilde Healthcare Services, a lower mid-market buy-out fund focused on Benelux and Germany, is looking for a student intern that is able to support the investment team with its activities.

Given the compact investment team, the intern will have the opportunity to take an integral role in a deal team. The intern will have the opportunity to engage in many parts of the investment process, with an emphasis on the deal origination phase. Strong analytical skills, an excellent track record and an entrepreneurial spirit are therefore required. We assume fluency in English and either Dutch or German. A previous internship in corporate finance, strategy consultancy or private equity is appreciated. You will work 3 (or more) months in the city of Utrecht as member of our investment team.

More information: More information on Gilde Healthcare: gildehealthcare.com More information on this position: Mr. T. Klein Robbenhaar, robbenhaar@gildehealthcare.com When interested, please send your resume and concise motivational email and we will be in contact with you.

 

 

Gilde Healthcare company Mainstay Medical Announces Exclusive Coverage of ReActiv8® by Anthem Blue Cross/Blue Shield

Mainstay Medical Holdings plc today announced that Anthem Blue Cross and Blue Shield (“Anthem”) has established favorable coverage for the company’s ReActiv8 Restorative NeurostimulationTM therapy for the treatment of intractable chronic low back pain. ReActiv8...
28. April 2025

Gilde Healthcare company Tagworks Pharmaceuticals Announces FDA Clearance of IND Application and Initiation of Phase 1 Clinical Trial for TGW101

TGW101 is a next-generation, first-in-class ADC targeting TAG-72 with an MMAE payload, developed based on Tagworks proprietary Click-to-Release linker chemistry; TGW101 is the first bioorthogonal, in vivo click chemistry-activated ADC, which enables superior control of...
22. April 2025

Gilde Healthcare company SynOx Therapeutics announces Board Chair transition to align with advancing Regulatory and Commercialization Strategy

SynOx Therapeutics Limited (“SynOx”), a late-stage clinical biopharmaceutical company developing of emactuzumab for Tenosynovial Giant Cell Tumours (TGCT), today announced the execution of a planned and orderly transition of its board chair position. Philip Astley-Sparke...
1. April 2025